September 20th 2024
Peptides are increasingly used in cosmeceuticals for their ability to enhance cellular communication and functionality in antiaging formulations.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Total body photography not standard of care
September 1st 2006Eckley M. Keach's article in the June 2006 issue of Dermatology Times ("Successful malpractice defense lies in body of evidence") provides tips for dermatologists to reduce the risk of malpractice liability from treating high-risk melanoma patients.
Cosmeceuticals may help some of the time, but jury is out on wrinkles
August 1st 2006Scottsdale, Ariz. - For dermatologists interested in the in-office dispensing of cosmeceuticals, three agents in particular - ferulic acid, idebenone and human growth factors - are gaining prominence, but is there evidence to back them up?
Ron Reagan pleads for support for stem cell research
July 29th 2006Stem cell research is among the "one or two paradigm-changing medical breakthroughs" that may occur in a lifetime, and it's vitally needed to bring hope to millions, says Ron Reagan, son of the late President Ronald Reagan. Mr. Reagan addressed the Friday morning plenary session at the American Academy of Dermatology's Academy '06, couching in impassioned and often stinging political commentary his plea for support for stem cell research.
Immune response modifier post-op
July 1st 2006San Francisco - Results from several studies performed with imiquimod 5 percent cream (Aldara, 3M Pharmaceuticals) suggest that the immune response modifier may have a role as a surgical adjuvant for improving local tumor control and/or to enhance scar appearance, says James M. Spencer, M.D., M.S., clinical professor of dermatology, Mt. Sinai School of Medicine, New York.
Take conservative approach to enjoy CO2 's plentiful benefits
July 1st 2006Scottsdale, Ariz. - Although it remains the gold standard for skin rejuvenation, CO2 laser resurfacing is paradoxically losing favor due to drawbacks ranging from the risk of complications to increasing patient reluctance over downtime and concerns about the complications.
Juvederm approval broadens filler options
July 1st 2006Irvine, Calif. - The Food and Drug Administration 's approval of the Juvederm gel (hyaluronic acid/HA, Allergan) product family could threaten Restylane's (Medicis) dominance of the dermal filler category while expanding the facial aesthetic marketplace, sources tell Dermatology Times.